3-hydroxybutyric acid has been researched along with Diabetes Mellitus, Adult-Onset in 96 studies
3-Hydroxybutyric Acid: BUTYRIC ACID substituted in the beta or 3 position. It is one of the ketone bodies produced in the liver.
3-hydroxybutyric acid : A straight-chain 3-hydroxy monocarboxylic acid comprising a butyric acid core with a single hydroxy substituent in the 3- position; a ketone body whose levels are raised during ketosis, used as an energy source by the brain during fasting in humans. Also used to synthesise biodegradable plastics.
| Excerpt | Relevance | Reference |
|---|---|---|
| "3 ng/mL, means +/- SE), the clinical and metabolic effects of benfluorex (B), a lipid-lowering drug able to improve insulin sensitivity." | 9.08 | Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo. ( Camisasca, R; Cassisa, C; Pacchioni, M; Piatti, PM; Pontiroli, AE; Pozza, G, 1996) |
| " In order to study the effect of HMG-CoA reductase inhibitor (pravastatin) on ketone formation, changes in the plasma levels of ketone bodies by treatment with pravastatin were studied in 18 non-insulin dependent diabetics with hypercholesterolemia." | 7.70 | Effect of pravastatin on plasma ketone bodies in diabetics with hypercholesterolemia. ( Chiba, T; Fukuda, M; Nagakubo, H; Ogawa, S; Oouchi, M; Sato, C; Sato, T; Sugimura, K, 1998) |
| "Three clinical studies were conducted: a bariatric surgery cohort study of participants with morbid obesity who underwent either Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG) studied over four and twelve weeks, and two randomized placebo-controlled, crossover double blind studies of liraglutide vs." | 5.69 | Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity. ( Alexandrou, A; Angelidi, AM; Connelly, MA; Kokkinos, A; Mantzoros, CS; Mingrone, G; Sanoudou, D, 2023) |
| "To examine whether the circulating substrate mix may be related to the incidence of heart failure (HF) and cardiovascular (CV) mortality and how it is altered by canagliflozin treatment." | 5.51 | Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS). ( Baldi, S; Ferrannini, E; Figtree, GA; Hansen, MK; Mahaffey, KW; Neal, B; Perkovic, V; Rosenthal, N; Scozzaro, T; Shaw, W; Tesfaye, F; Tsimihodimos, V, 2022) |
| "Euglycaemic ketoacidosis has been reported after sodium-glucose cotransporter 2 (SGLT2) inhibitor treatment." | 5.48 | Degree of ketonaemia and its association with insulin resistance after dapagliflozin treatment in type 2 diabetes. ( Baek, SI; Choi, SH; Jang, HC; Kim, KM; Lee, DH; Lim, S; Min, SH; Moon, JH; Oh, TJ; Park, KS, 2018) |
| "The incidence of obesity and type 2 diabetes mellitus (T2DM) is increasing, and new experimental models are required to investigate the diverse aspects of these polygenic diseases, which are intimately linked in terms of aetiology." | 5.37 | Effect of trans-fat, fructose and monosodium glutamate feeding on feline weight gain, adiposity, insulin sensitivity, adipokine and lipid profile. ( Al-Mohanna, FA; Bakheet, R; Burrows, J; Collison, KS; Inglis, A; Makhoul, NJ; Milgram, NW; Mondreal, R; Saleh, SM; Zaidi, MZ, 2011) |
| "3 ng/mL, means +/- SE), the clinical and metabolic effects of benfluorex (B), a lipid-lowering drug able to improve insulin sensitivity." | 5.08 | Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo. ( Camisasca, R; Cassisa, C; Pacchioni, M; Piatti, PM; Pontiroli, AE; Pozza, G, 1996) |
| " As alterations in hepatic gluconeogenesis and glycogen metabolism are hallmarks that characterize insulin resistance and type 2 diabetes, we tested whether imposed changes in the extracellular redox state could modulate these processes." | 3.81 | The extracellular redox state modulates mitochondrial function, gluconeogenesis, and glycogen synthesis in murine hepatocytes. ( Corkey, BE; Jones Iv, AR; Kleckner, AS; Liesa, M; Nocito, L; Yoo, EJ, 2015) |
| " g body wt-1 for each administration), failed to prevent the fall in body weight, liver and muscle glycogen contents, and plasma d-glucose or insulin concentration, as well as the increase in plasma free fatty acid and beta-hydroxybutyrate concentrations caused by starvation." | 3.70 | Assessment of the nutritional value of glycerol-1,2, 3-tris(methylsuccinate) in fed and starved rats. ( Björkling, F; Ladrière, L; Malaisse, WJ, 1999) |
| " In order to study the effect of HMG-CoA reductase inhibitor (pravastatin) on ketone formation, changes in the plasma levels of ketone bodies by treatment with pravastatin were studied in 18 non-insulin dependent diabetics with hypercholesterolemia." | 3.70 | Effect of pravastatin on plasma ketone bodies in diabetics with hypercholesterolemia. ( Chiba, T; Fukuda, M; Nagakubo, H; Ogawa, S; Oouchi, M; Sato, C; Sato, T; Sugimura, K, 1998) |
| "Eighteen patients with type 2 diabetes received i." | 2.94 | Effects of β-hydroxybutyrate on cognition in patients with type 2 diabetes. ( Fenger, M; Ingerslev, JS; Jensen, NJ; Miskowiak, KW; Møller, N; Nilsson, M; Olsen, DA; Rungby, J; Svart, M; Zander, M, 2020) |
| "We examined patients with NIDDM to find whether maintaining plasma FFA levels in the fasting range with a euglycemic hyperinsulinemic clamp combined with an oral glucose load (clamp OGL) would affect insulin-mediated peripheral glucose uptake (PGU) and splanchnic glucose uptake (SGU)." | 2.69 | High plasma free fatty acids decrease splanchnic glucose uptake in patients with non-insulin-dependent diabetes mellitus. ( Hori, M; Ikeda, M; Katsura, M; Kubota, M; Matsuhisa, M; Nakahara, I; Shiba, Y; Tohdo, R; Tomita, T; Yamasaki, Y, 1998) |
| "Thus, in NIDDM, BAYm 1099 was effective in diminishing and delaying postprandial excursions of blood glucose, lactate, and pyruvate after high- and low-sucrose meals, but overall metabolic control remained unchanged." | 2.66 | Effects of BAYm 1099, new alpha-glucosidase inhibitor, on acute metabolic responses and metabolic control in NIDDM over 1 mo. ( Alberti, KG; Samad, AH; Taylor, R; Ty Willing, TS, 1988) |
| "A complication of diabetes is diabetic ketoacidosis (DKA), which if left untreated is a life threatening condition." | 2.53 | Evaluation of the Accuracy of Capillary Hydroxybutyrate Measurement Compared with Other Measurements in the Diagnosis of Diabetic Ketoacidosis: A Systematic Review. ( Brooke, J; Ojo, O; Stiell, M, 2016) |
| "With rising incidence and prevalence of type 2 diabetes, prevention including identification of prospective biomarkers becomes increasingly relevant." | 1.91 | Fasting Ketone Bodies and Incident Type 2 Diabetes in the General Population. ( Bakker, SJL; Connelly, MA; de Borst, MH; Dullaart, RPF; Gansevoort, RT; Garcia, E; Szili-Torok, T; Tietge, UJF, 2023) |
| "Patients with diabetic ketosis often exhibit albuminuria." | 1.72 | Beta-Hydroxybutyric Acid Inhibits Renal Tubular Reabsorption via the AKT/DAB2/Megalin Signalling Pathway. ( Chang, B; Cui, X; Gao, Z; Li, X; Li, Y; Meng, C; Shan, C; Song, Q; Wang, J; Yang, J; Zuo, M, 2022) |
| "However, existing therapeutics for type 2 diabetes mellitus have limited success on the prevention of diabetic cardiomyopathy." | 1.62 | Ketone Ester D-β-Hydroxybutyrate-(R)-1,3 Butanediol Prevents Decline in Cardiac Function in Type 2 Diabetic Mice. ( Bers, DM; Chiamvimonvat, N; Dedkova, EN; King, MT; Miller, CV; Schaefer, S; Thai, PN; Veech, RL, 2021) |
| "There were 23 admissions for diabetic ketoacidosis (DKA) or hyperosmolar state." | 1.51 | The Significance of an Increased Beta-Hydroxybutyrate at Presentation to the Emergency Department in Patients with Diabetes in the Absence of a Hyperglycemic Emergency. ( Chiew, AL; Depczynski, B; Lee, ATK; Varndell, W, 2019) |
| "Euglycemic ketoacidosis has been reported in patients with type 2 diabetes and in patients with type 1 diabetes." | 1.51 | Ketoacidosis in Euglycemic Patients With Type 2 Diabetes After Abdominal Surgery. ( Bennett, A; Geehan, D; Moncure, M; Segebrecht, R; Van Way, CW; Weide, L, 2019) |
| "The eruptive xanthoma lesions gradually diminished in size and number and eventually disappeared by 12 months." | 1.51 | Eruptive xanthomas in a patient with soft-drink diabetic ketosis and apolipoprotein E4/2. ( Aiba, S; Imai, J; Katagiri, H; Kikuchi, K; Kohata, M; Kurosawa, S; Nakajima, T; Satake, C; Sawada, S; Takahashi, K; Takeda, K; Tsuchiya, S, 2019) |
| "Euglycaemic ketoacidosis has been reported after sodium-glucose cotransporter 2 (SGLT2) inhibitor treatment." | 1.48 | Degree of ketonaemia and its association with insulin resistance after dapagliflozin treatment in type 2 diabetes. ( Baek, SI; Choi, SH; Jang, HC; Kim, KM; Lee, DH; Lim, S; Min, SH; Moon, JH; Oh, TJ; Park, KS, 2018) |
| "Breath acetone of the type 2 diabetes mellitus patients showed positive correlations with plasma glucose when the level of plasma glucose tended to decrease during hospitalization." | 1.40 | Analysis of ketone bodies in exhaled breath and blood of ten healthy Japanese at OGTT using a portable gas chromatograph. ( Hinokio, Y; Koseki, T; Takahashi, N; Tanda, N; Washio, J, 2014) |
| "The incidence of obesity and type 2 diabetes mellitus (T2DM) is increasing, and new experimental models are required to investigate the diverse aspects of these polygenic diseases, which are intimately linked in terms of aetiology." | 1.37 | Effect of trans-fat, fructose and monosodium glutamate feeding on feline weight gain, adiposity, insulin sensitivity, adipokine and lipid profile. ( Al-Mohanna, FA; Bakheet, R; Burrows, J; Collison, KS; Inglis, A; Makhoul, NJ; Milgram, NW; Mondreal, R; Saleh, SM; Zaidi, MZ, 2011) |
| "From 450 type 2 diabetes mellitus insulin-treated patients attending the ER with a capillary glucose level >13." | 1.36 | The performance of a glucose-ketone meter in the diagnosis of diabetic ketoacidosis in patients with type 2 diabetes in the emergency room. ( Tentolouris, N; Voulgari, C, 2010) |
| "Current criteria for the diagnosis of diabetic ketoacidosis (DKA) are limited by their nonspecificity (serum bicarbonate [HCO(3)] and pH) and qualitative nature (the presence of ketonemia/ketonuria)." | 1.35 | Can serum beta-hydroxybutyrate be used to diagnose diabetic ketoacidosis? ( Basu, A; Karon, BS; Kudva, YC; Miles, JM; Muller, LA; Schwenk, WF; Sheikh-Ali, M; Xu, J, 2008) |
| "As L-carnitine plays a pivotal role in the balanced metabolism of fatty acids and carbohydrates, this study was carried out to investigate whether long-term mildronate treatment could influence glucose levels and prevent diabetic complications in an experimental model of type 2 diabetes in Goto-Kakizaki (GK) rats." | 1.35 | Protective effects of mildronate in an experimental model of type 2 diabetes in Goto-Kakizaki rats. ( Cirule, H; Dambrova, M; Grinberga, S; Kalvinsh, I; Kuka, J; Liepinsh, E; Skapare, E; Svalbe, B; Vilskersts, R; Zvejniece, L, 2009) |
| "These mice also exhibited features of type 2 diabetes with increased hepatic gluconeogenesis, increased lipogenic gene expression, and low serum beta-hydroxybutyrate." | 1.35 | Ablation of ARNT/HIF1beta in liver alters gluconeogenesis, lipogenic gene expression, and serum ketones. ( Goldfine, A; Gonzalez, FJ; Gunton, JE; Kahn, CR; Lee, K; Patti, ME; Ruderman, NB; Saha, AK; Suzuki, R; Tran, T; Wang, XL, 2009) |
| "Patients with type 2 diabetes (T2DM) tend to loose more lean body mass during both long-term weight reduction and short-term very-low-calorie diet." | 1.34 | Analysis of factors influencing nitrogen balance during acute starvation in obese subject with and without type 2 diabetes. ( Andel, M; Duska, F; Kubena, A; Mokrejs, P; Tůma, P, 2007) |
| "Our results suggest that genetic susceptibility plays an important role in inducing underdevelopment and NTD in cultured CDs embryos in sub-teratogenic medium and in protecting the CDr embryos under the same conditions." | 1.32 | Reduced SOD activity and increased neural tube defects in embryos of the sensitive but not of the resistant Cohen diabetic rats cultured under diabetic conditions. ( Ornoy, A; Weksler-Zangen, S; Yaffe, P, 2003) |
| "We conclude that in type 2 diabetes, both liver and kidney contribute to glucose overproduction and that renal glucose uptake is markedly increased." | 1.30 | Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus. ( Dostou, J; Gerich, J; Meyer, C; Mitrakou, A; Nadkarni, V; Stumvoll, M, 1998) |
| "Glycerol, which was present in the infused lipid (272 mmol/l) did not affect ISR." | 1.30 | Effects of fatty acids and ketone bodies on basal insulin secretion in type 2 diabetes. ( Boden, G; Chen, X, 1999) |
| " The animals receiving the low-fat meal at dosing and at 4 h post-dose exhibited similar extents of absorption, as shown by similar AUC values and urinary radioactivity recovery." | 1.29 | The effect of the fat content of food on the pharmacokinetics and pharmacodynamics of SDZ FOX 988, an antidiabetic agent, in the dog. ( Aun, RL; Kalafsky, G; Lau, DT; Tse, FL, 1995) |
| "Thus, in NIDDM patients, fasting corrects the defect in glycogen storage without modifying the action of insulin on glucose uptake and improves beta-cell responsiveness, the latter two effects being opposite to those observed in nondiabetic subjects." | 1.29 | Glucose metabolism during the starved-to-fed transition in obese patients with NIDDM. ( Balasse, EO; Féry, F, 1994) |
| "In the NIDDM-B group, blood alcohol (ethyl alcohol) concentration was very low." | 1.28 | Effects of chronic alcohol intake on carbohydrate and lipid metabolism in subjects with type II (non-insulin-dependent) diabetes. ( Avogaro, A; Ben, G; Duner, E; Gigante, A; Gnudi, L; Iori, E; Maran, A; Tiengo, A, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (5.21) | 18.7374 |
| 1990's | 27 (28.13) | 18.2507 |
| 2000's | 16 (16.67) | 29.6817 |
| 2010's | 30 (31.25) | 24.3611 |
| 2020's | 18 (18.75) | 2.80 |
| Authors | Studies |
|---|---|
| Thai, PN | 1 |
| Miller, CV | 1 |
| King, MT | 1 |
| Schaefer, S | 1 |
| Veech, RL | 1 |
| Chiamvimonvat, N | 1 |
| Bers, DM | 1 |
| Dedkova, EN | 1 |
| Soto-Mota, A | 1 |
| Norwitz, NG | 1 |
| Evans, RD | 1 |
| Clarke, K | 1 |
| Costabile, G | 1 |
| Della Pepa, G | 1 |
| Salamone, D | 1 |
| Luongo, D | 1 |
| Naviglio, D | 1 |
| Brancato, V | 1 |
| Cavaliere, C | 1 |
| Salvatore, M | 1 |
| Cipriano, P | 1 |
| Vitale, M | 1 |
| Corrado, A | 1 |
| Rivellese, AA | 1 |
| Annuzzi, G | 1 |
| Bozzetto, L | 1 |
| Ferrannini, E | 3 |
| Baldi, S | 2 |
| Scozzaro, T | 1 |
| Tsimihodimos, V | 1 |
| Tesfaye, F | 1 |
| Shaw, W | 1 |
| Rosenthal, N | 1 |
| Figtree, GA | 1 |
| Neal, B | 1 |
| Mahaffey, KW | 1 |
| Perkovic, V | 1 |
| Hansen, MK | 1 |
| Zuo, M | 1 |
| Meng, C | 1 |
| Song, Q | 1 |
| Gao, Z | 1 |
| Cui, X | 1 |
| Wang, J | 2 |
| Li, Y | 2 |
| Li, X | 2 |
| Shan, C | 1 |
| Yang, J | 3 |
| Chang, B | 2 |
| Angelidi, AM | 1 |
| Kokkinos, A | 1 |
| Sanoudou, D | 1 |
| Connelly, MA | 2 |
| Alexandrou, A | 1 |
| Mingrone, G | 1 |
| Mantzoros, CS | 1 |
| Han, HJ | 1 |
| Cole, AE | 1 |
| Verma, A | 1 |
| Lee, M | 2 |
| Cho, Y | 1 |
| Lee, YH | 2 |
| Kang, ES | 2 |
| Cha, BS | 2 |
| Lee, BW | 2 |
| Lee, S | 1 |
| Bae, J | 1 |
| Jo, DR | 1 |
| Gilchrist, HE | 1 |
| Hatton, CJ | 1 |
| Roginski, MA | 1 |
| Esteves, AM | 1 |
| Szili-Torok, T | 1 |
| de Borst, MH | 1 |
| Garcia, E | 1 |
| Gansevoort, RT | 1 |
| Dullaart, RPF | 1 |
| Bakker, SJL | 1 |
| Tietge, UJF | 1 |
| Lee, YK | 1 |
| Oh, TJ | 2 |
| Lee, JI | 1 |
| Choi, BY | 1 |
| Cho, HC | 1 |
| Jang, HC | 2 |
| Choi, SH | 2 |
| Liu, Y | 2 |
| Xu, F | 1 |
| Zhang, S | 1 |
| Cui, S | 1 |
| Wang, X | 1 |
| Zheng, H | 1 |
| Li, J | 2 |
| Kong, Y | 1 |
| Jiang, X | 1 |
| Depczynski, B | 1 |
| Lee, ATK | 1 |
| Varndell, W | 1 |
| Chiew, AL | 1 |
| Jensen, NJ | 1 |
| Nilsson, M | 1 |
| Ingerslev, JS | 1 |
| Olsen, DA | 1 |
| Fenger, M | 1 |
| Svart, M | 1 |
| Møller, N | 1 |
| Zander, M | 1 |
| Miskowiak, KW | 1 |
| Rungby, J | 1 |
| Nuttall, FQ | 2 |
| Almokayyad, RM | 1 |
| Gannon, MC | 2 |
| Fikri, AM | 1 |
| Smyth, R | 1 |
| Kumar, V | 1 |
| Al-Abadla, Z | 1 |
| Abusnana, S | 1 |
| Munday, MR | 1 |
| Inaba, M | 1 |
| Kumeda, Y | 1 |
| Yamada, S | 1 |
| Toi, N | 1 |
| Hamai, C | 1 |
| Noguchi, K | 1 |
| Yasuda, E | 1 |
| Furumitsu, Y | 1 |
| Emoto, M | 1 |
| Ohno, Y | 1 |
| McKenzie, AL | 1 |
| Athinarayanan, SJ | 1 |
| McCue, JJ | 1 |
| Adams, RN | 1 |
| Keyes, M | 1 |
| McCarter, JP | 1 |
| Volek, JS | 1 |
| Phinney, SD | 1 |
| Hallberg, SJ | 1 |
| Kołodziejski, PA | 1 |
| Pruszyńska-Oszmałek, E | 1 |
| Strowski, MZ | 1 |
| Nowak, KW | 1 |
| Lowe, WL | 1 |
| Bain, JR | 1 |
| Nodzenski, M | 1 |
| Reisetter, AC | 1 |
| Muehlbauer, MJ | 1 |
| Stevens, RD | 1 |
| Ilkayeva, OR | 1 |
| Lowe, LP | 1 |
| Metzger, BE | 1 |
| Newgard, CB | 1 |
| Scholtens, DM | 1 |
| Min, SH | 1 |
| Baek, SI | 1 |
| Lee, DH | 1 |
| Kim, KM | 1 |
| Moon, JH | 1 |
| Park, KS | 1 |
| Lim, S | 1 |
| Singh, SK | 1 |
| Singh, VK | 1 |
| Kumari, P | 1 |
| Nakade, UP | 1 |
| Garg, SK | 1 |
| Polidori, D | 1 |
| Iijima, H | 1 |
| Goda, M | 1 |
| Maruyama, N | 1 |
| Inagaki, N | 1 |
| Crawford, PA | 1 |
| Tsuchiya, S | 1 |
| Sawada, S | 1 |
| Takeda, K | 1 |
| Takahashi, K | 1 |
| Nakajima, T | 1 |
| Kohata, M | 1 |
| Kurosawa, S | 1 |
| Satake, C | 1 |
| Imai, J | 1 |
| Kikuchi, K | 1 |
| Aiba, S | 1 |
| Katagiri, H | 1 |
| Segebrecht, R | 1 |
| Moncure, M | 1 |
| Bennett, A | 1 |
| Geehan, D | 1 |
| Van Way, CW | 1 |
| Weide, L | 1 |
| Thapa, SS | 1 |
| Lal, A | 1 |
| Omer, A | 1 |
| Trivedi, N | 1 |
| Arildsen, L | 1 |
| Andersen, JV | 1 |
| Waagepetersen, HS | 1 |
| Nissen, JBD | 1 |
| Sheykhzade, M | 1 |
| Mahendran, Y | 1 |
| Vangipurapu, J | 1 |
| Cederberg, H | 1 |
| Stancáková, A | 1 |
| Pihlajamäki, J | 1 |
| Soininen, P | 1 |
| Kangas, AJ | 1 |
| Paananen, J | 1 |
| Civelek, M | 1 |
| Saleem, NK | 1 |
| Pajukanta, P | 1 |
| Lusis, AJ | 1 |
| Bonnycastle, LL | 1 |
| Morken, MA | 1 |
| Collins, FS | 1 |
| Mohlke, KL | 1 |
| Boehnke, M | 1 |
| Ala-Korpela, M | 1 |
| Kuusisto, J | 1 |
| Laakso, M | 1 |
| Sadek, KM | 1 |
| Shaheen, H | 1 |
| Samudrala, D | 1 |
| Lammers, G | 1 |
| Mandon, J | 1 |
| Blanchet, L | 1 |
| Schreuder, TH | 1 |
| Hopman, MT | 1 |
| Harren, FJ | 1 |
| Tappy, L | 1 |
| Cristescu, SM | 1 |
| Newman, JC | 1 |
| Verdin, E | 1 |
| Ke, P | 1 |
| Zhou, H | 1 |
| Wang, Z | 1 |
| Wu, X | 1 |
| Lin, H | 1 |
| Huang, X | 1 |
| Tanda, N | 1 |
| Hinokio, Y | 1 |
| Washio, J | 1 |
| Takahashi, N | 1 |
| Koseki, T | 1 |
| Levy, M | 1 |
| Thaiss, CA | 1 |
| Elinav, E | 1 |
| Nocito, L | 1 |
| Kleckner, AS | 1 |
| Yoo, EJ | 1 |
| Jones Iv, AR | 1 |
| Liesa, M | 1 |
| Corkey, BE | 1 |
| Li, D | 1 |
| Zhang, Y | 1 |
| Sun, R | 1 |
| Xia, M | 1 |
| Giesbertz, P | 1 |
| Padberg, I | 1 |
| Rein, D | 1 |
| Ecker, J | 1 |
| Höfle, AS | 1 |
| Spanier, B | 1 |
| Daniel, H | 1 |
| Frascerra, S | 1 |
| Astiarraga, B | 1 |
| Heise, T | 1 |
| Bizzotto, R | 1 |
| Mari, A | 1 |
| Pieber, TR | 1 |
| Muscelli, E | 1 |
| Mark, M | 1 |
| Mayoux, E | 1 |
| Brooke, J | 1 |
| Stiell, M | 1 |
| Ojo, O | 1 |
| Vigili de Kreutzenberg, S | 1 |
| Avogaro, A | 2 |
| Wang, XL | 1 |
| Suzuki, R | 1 |
| Lee, K | 1 |
| Tran, T | 1 |
| Gunton, JE | 1 |
| Saha, AK | 1 |
| Patti, ME | 1 |
| Goldfine, A | 1 |
| Ruderman, NB | 1 |
| Gonzalez, FJ | 1 |
| Kahn, CR | 1 |
| Liepinsh, E | 1 |
| Vilskersts, R | 1 |
| Zvejniece, L | 1 |
| Svalbe, B | 1 |
| Skapare, E | 1 |
| Kuka, J | 1 |
| Cirule, H | 1 |
| Grinberga, S | 1 |
| Kalvinsh, I | 1 |
| Dambrova, M | 1 |
| Voulgari, C | 1 |
| Tentolouris, N | 1 |
| Zhang, D | 1 |
| Yang, H | 1 |
| Kong, X | 1 |
| Wang, K | 1 |
| Mao, X | 1 |
| Yan, X | 1 |
| Wang, Y | 1 |
| Liu, S | 1 |
| Zhang, X | 1 |
| Chen, L | 1 |
| Wu, J | 1 |
| Wei, M | 1 |
| Guan, Y | 1 |
| Collison, KS | 1 |
| Zaidi, MZ | 1 |
| Saleh, SM | 1 |
| Inglis, A | 1 |
| Mondreal, R | 1 |
| Makhoul, NJ | 1 |
| Bakheet, R | 1 |
| Burrows, J | 1 |
| Milgram, NW | 1 |
| Al-Mohanna, FA | 1 |
| Oh, SJ | 1 |
| Choi, JM | 1 |
| Yun, KU | 1 |
| Oh, JM | 1 |
| Kwak, HC | 1 |
| Oh, JG | 1 |
| Lee, KS | 1 |
| Kim, BH | 1 |
| Heo, TH | 1 |
| Kim, SK | 1 |
| Xu, J | 2 |
| Liu, C | 1 |
| Cai, S | 1 |
| Dong, J | 1 |
| Feng, J | 1 |
| Chen, Z | 1 |
| Kazemi Khoo, N | 1 |
| Iravani, A | 1 |
| Arjmand, M | 1 |
| Vahabi, F | 1 |
| Lajevardi, M | 1 |
| Akrami, SM | 1 |
| Zamani, Z | 1 |
| Harano, Y | 1 |
| Weksler-Zangen, S | 1 |
| Yaffe, P | 1 |
| Ornoy, A | 1 |
| Seal, CJ | 1 |
| Daly, ME | 1 |
| Thomas, LC | 1 |
| Bal, W | 1 |
| Birkett, AM | 1 |
| Jeffcoat, R | 1 |
| Mathers, JC | 1 |
| Thiess, S | 1 |
| Becskei, C | 1 |
| Tomsa, K | 1 |
| Lutz, TA | 1 |
| Wanner, M | 1 |
| Sari, R | 1 |
| Balci, MK | 1 |
| Akbas, SH | 1 |
| Avci, B | 1 |
| Ravikumar, B | 1 |
| Carey, PE | 1 |
| Snaar, JE | 1 |
| Deelchand, DK | 1 |
| Cook, DB | 1 |
| Neely, RD | 1 |
| English, PT | 1 |
| Firbank, MJ | 1 |
| Morris, PG | 1 |
| Taylor, R | 3 |
| Yotsumoto, T | 1 |
| Naitoh, T | 1 |
| Kanaki, T | 1 |
| Tsuruzoe, N | 1 |
| Monti, LD | 2 |
| Setola, E | 1 |
| Fragasso, G | 1 |
| Camisasca, RP | 1 |
| Lucotti, P | 1 |
| Galluccio, E | 1 |
| Origgi, A | 1 |
| Margonato, A | 1 |
| Piatti, P | 1 |
| Pelletier, A | 1 |
| Coderre, L | 1 |
| Duska, F | 1 |
| Tůma, P | 1 |
| Mokrejs, P | 1 |
| Kubena, A | 1 |
| Andel, M | 1 |
| Sheikh-Ali, M | 1 |
| Karon, BS | 1 |
| Basu, A | 1 |
| Kudva, YC | 1 |
| Muller, LA | 1 |
| Schwenk, WF | 1 |
| Miles, JM | 1 |
| Schmitz, O | 1 |
| Rømer, FK | 1 |
| Alberti, KG | 7 |
| Hreidarsson, AB | 1 |
| Orskov, H | 2 |
| Nicholson, JK | 1 |
| O'Flynn, MP | 1 |
| Sadler, PJ | 1 |
| Macleod, AF | 1 |
| Juul, SM | 1 |
| Sönksen, PH | 1 |
| Lau, DT | 1 |
| Kalafsky, G | 1 |
| Aun, RL | 1 |
| Tse, FL | 1 |
| Féry, F | 1 |
| Balasse, EO | 1 |
| Berrish, TS | 1 |
| Elliott, C | 1 |
| Cooper, BG | 1 |
| Reed, JW | 1 |
| Walker, M | 3 |
| Akanji, AO | 1 |
| Osifo, E | 1 |
| Kirk, M | 1 |
| Hockaday, TD | 1 |
| Piatti, PM | 2 |
| Davis, SN | 1 |
| Conti, M | 1 |
| Brown, MD | 1 |
| Pozza, G | 2 |
| Pontiroli, AE | 1 |
| Pacchioni, M | 1 |
| Cassisa, C | 1 |
| Camisasca, R | 1 |
| Shelgikar, KM | 1 |
| Naik, SS | 1 |
| Khopkar, M | 1 |
| Bhat, DS | 1 |
| Raut, KN | 1 |
| Joglekar, CV | 1 |
| Gerard, ME | 1 |
| Yajnik, CS | 1 |
| Pounder, DJ | 1 |
| Stevenson, RJ | 1 |
| Taylor, KK | 1 |
| Meyer, C | 1 |
| Stumvoll, M | 1 |
| Nadkarni, V | 1 |
| Dostou, J | 1 |
| Mitrakou, A | 1 |
| Gerich, J | 1 |
| Tomita, T | 1 |
| Yamasaki, Y | 1 |
| Kubota, M | 1 |
| Tohdo, R | 1 |
| Katsura, M | 1 |
| Ikeda, M | 1 |
| Nakahara, I | 1 |
| Shiba, Y | 1 |
| Matsuhisa, M | 1 |
| Hori, M | 1 |
| Sato, T | 1 |
| Oouchi, M | 1 |
| Nagakubo, H | 1 |
| Chiba, T | 1 |
| Ogawa, S | 1 |
| Sato, C | 1 |
| Sugimura, K | 1 |
| Fukuda, M | 1 |
| Boden, G | 2 |
| Chen, X | 2 |
| Iqbal, N | 1 |
| Svedman, C | 1 |
| Samra, JS | 1 |
| Clark, ML | 1 |
| Levy, JC | 1 |
| Frayn, KN | 1 |
| Ladrière, L | 1 |
| Björkling, F | 1 |
| Malaisse, WJ | 1 |
| Szabó, Z | 2 |
| Arnqvist, H | 1 |
| Håkanson, E | 2 |
| Jorfeldt, L | 2 |
| Svedjeholm, R | 2 |
| Fulcher, GR | 2 |
| Catalano, C | 2 |
| Farrer, M | 1 |
| Agius, L | 1 |
| McGarry, JD | 1 |
| Eckel, RH | 1 |
| Hanson, AS | 1 |
| Chen, AY | 1 |
| Berman, JN | 1 |
| Yost, TJ | 1 |
| Brass, EP | 1 |
| Watanabe, T | 1 |
| Sugiyama, H | 1 |
| Uchimura, I | 1 |
| Maezawa, H | 1 |
| Suzuki, M | 1 |
| Kosegawa, I | 1 |
| Miura, S | 1 |
| Negishi, K | 1 |
| Itabashi, A | 1 |
| Katayama, S | 1 |
| Ishii, J | 1 |
| Kamata, S | 1 |
| Fujita, C | 1 |
| Johnson, AB | 1 |
| Argyraki, M | 1 |
| Thow, JC | 1 |
| Jones, IR | 1 |
| Broughton, D | 1 |
| Miller, M | 1 |
| Ratheiser, K | 1 |
| Schneeweiss, B | 1 |
| Waldhäusl, W | 1 |
| Fasching, P | 1 |
| Korn, A | 1 |
| Nowotny, P | 1 |
| Rohac, M | 1 |
| Wolf, HP | 1 |
| Ben, G | 1 |
| Gnudi, L | 1 |
| Maran, A | 1 |
| Gigante, A | 1 |
| Duner, E | 1 |
| Iori, E | 1 |
| Tiengo, A | 1 |
| Ubukata, E | 1 |
| Hepp, KD | 1 |
| Bauersachs, R | 1 |
| Piwernetz, K | 1 |
| Renner, R | 1 |
| Watts, NB | 1 |
| DiGirolamo, M | 1 |
| Capaldo, B | 1 |
| Santoro, D | 1 |
| Riccardi, G | 1 |
| Perrotti, N | 1 |
| Saccà, L | 1 |
| Samad, AH | 1 |
| Ty Willing, TS | 1 |
| Thomas, DJ | 1 |
| Platt, HS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Medium-term Effects of a Portfolio Diet on Non-alcoholic Fatty Liver Disease in Type 2 Diabetic Patients[NCT03380416] | 49 participants (Actual) | Interventional | 2017-04-04 | Completed | |||
| A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of JNJ-28431754 on Cardiovascular Outcomes in Adult Subjects With Type 2 Diabetes Mellitus[NCT01032629] | Phase 3 | 4,330 participants (Actual) | Interventional | 2009-12-09 | Completed | ||
| A Comparative Study of the Effects of Roux en Y Gastric Bypass and Sleeve Gastrectomy on Postprandial Gut Hormone Responses, Glycemia and Lipid Profile, Weight Loss, and Indices of Cardiovascular Risk[NCT03851874] | 28 participants (Actual) | Interventional | 2011-10-31 | Completed | |||
| Liraglutide in Obesity and Diabetes: Identification of CNS Targets Using fMRI[NCT01562678] | Phase 4 | 28 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| Saxenda: Underlying Mechanisms and Clinical Outcomes[NCT02944500] | Phase 4 | 28 participants (Actual) | Interventional | 2016-11-30 | Active, not recruiting | ||
| A Phase 2 Open Label Randomized Controlled Trial Determir Vs Neutral Protamine Hagedorn (NPH) In Pregnant Women: DETERMINE Study[NCT05124457] | Phase 2 | 336 participants (Anticipated) | Interventional | 2022-02-01 | Recruiting | ||
| Development of Ketoacidosis During the Perioperative Period: an Observational Study 'The DKAP Study'[NCT05225467] | 58 participants (Actual) | Observational [Patient Registry] | 2022-03-15 | Completed | |||
| Effect of Purified Anthocyanin on Oxidative Stress and Glycemic Control in Subjects With Type 2 Diabetes Mellitus: A Randomized, Double-Blinded, Placebo-Controlled Trial[NCT02317211] | Early Phase 1 | 70 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| Effects of SGLT-2 Inhibitor on Myocardial Perfusion, Function and Metabolism in Type 2 DM Patients at High Cardiovascular Risk: The SIMPle Randomized Clinical Trial[NCT03151343] | Phase 3 | 92 participants (Actual) | Interventional | 2017-03-29 | Completed | ||
| Sodium-Glucose Cotransporter-2 Inhibitors: A Potential Novel Treatment for Epilepsy[NCT05512130] | Early Phase 1 | 18 participants (Anticipated) | Interventional | 2022-08-17 | Recruiting | ||
| Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease[NCT05719714] | Phase 1/Phase 2 | 60 participants (Anticipated) | Interventional | 2023-11-01 | Recruiting | ||
| Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in Patients With Type II Diabetes Mellitus[NCT05164263] | Phase 4 | 156 participants (Anticipated) | Interventional | 2021-04-01 | Recruiting | ||
| The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes[NCT02964715] | Phase 4 | 25 participants (Anticipated) | Interventional | 2016-11-30 | Recruiting | ||
| Effect of a Quadruple Therapy on Pancreatic Islet Function, Insulin Resistance and Cardiovascular Function in Patients With Mixed Prediabetes and Obesity: Randomized Clinical Trial[NCT04131582] | Phase 3 | 34 participants (Anticipated) | Interventional | 2019-09-01 | Recruiting | ||
| Effect of Dapagliflozin on Nighttime Blood Pressure in Type 2 Diabetes[NCT03887416] | Phase 4 | 225 participants (Anticipated) | Interventional | 2019-04-12 | Recruiting | ||
| Improvement of Myocardial Function and Metabolic Syndrome in Type 2 Diabetes Patients by a Low Glycemic and Insulinemic Diet (LOGI®) Compared to the Traditional Low Fat Diet - a Prospective Parallel Group/Cross Over Study[NCT01004757] | 41 participants (Anticipated) | Interventional | 2008-02-29 | Active, not recruiting | |||
| The Effect of Ingestion of Foods on the Plasma Glucose and Insulin Response in Subjects With Type 2 Diabetes: Protein, Amino Acids & Insulin & Glucagon Secretion in Humans[NCT01471509] | 300 participants (Anticipated) | Interventional | 1982-08-31 | Suspended (stopped due to Lack of funding) | |||
| The Effect of Acipimox on GLP-1 Secretion in Healthy Subjects: a Pilot Study[NCT02796950] | 8 participants (Actual) | Interventional | 2016-06-30 | Completed | |||
| Modulating Physiologic Effects Of Phospholipid Metabolism In Obesity And Diabetes; AIM 4: Composition and Function of Sarcoplasmic Reticulum in Persons With the Metabolic Syndrome[NCT02122666] | 100 participants (Anticipated) | Observational | 2014-03-31 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change from baseline in Estimated Glomerular Filtration Rate (eGFR) was assessed at end of treatment. GFR is a measure of the rate at which blood is filtered by the kidney. Modification of Diet in Renal Disease (MDRD) is an equation (calculation) used to estimate GFR in participants with impaired renal function based on serum creatinine, age, race, and sex. eGFR milliliters/minute/1.73 meters square (mL/min/1.73 m^2) = 175 * (serum creatinine) ^ 1.154 * (Age) ^-0.203 *(0.742 if female) * (1.21 if Black). (NCT01032629)
Timeframe: Baseline and end of treatment (approximately 338 weeks)
| Intervention | mL/min/1.73 m^2 (Least Squares Mean) |
|---|---|
| Placebo | -5.23 |
| Canagliflozin 100 mg | -3.55 |
| Canagliflozin 300 mg | -3.98 |
Change from baseline in the fasting plasma glucose levels at end-of-treatment was assessed. (NCT01032629)
Timeframe: Baseline and end of treatment (approximately 338 weeks)
| Intervention | Millimoles per liter (mmol/L) (Least Squares Mean) |
|---|---|
| Placebo | 0.16 |
| Canagliflozin 100 mg | -0.42 |
| Canagliflozin 300 mg | -0.57 |
Change from baseline in glycated hemoglobin (HbA1c) percentage (%) was assessed at end of treatment. Glycated hemoglobin is a form of hemoglobin that is measured primarily to identify the average glucose concentration in the blood. (NCT01032629)
Timeframe: Baseline and end of treatment (approximately 338 weeks)
| Intervention | HbA1c (%) (Least Squares Mean) |
|---|---|
| Placebo | 0.01 |
| Canagliflozin 100 mg | -0.26 |
| Canagliflozin 300 mg | -0.31 |
The homeostatic model assessment (HOMA) quantifies insulin resistance and beta-cell function. HOMA2-%B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady-state beta cell function (%B) as a percentage of a normal reference population (normal young adults). The normal reference population was set at 100 percent. (NCT01032629)
Timeframe: Baseline and end of treatment (approximately 338 weeks)
| Intervention | Percentage of HOMA2 (Least Squares Mean) |
|---|---|
| Placebo | 4.02 |
| Canagliflozin 100 mg | 6.82 |
| Canagliflozin 300 mg | 8.09 |
Change from baseline in LDL-C to HDL-C ratio was assessed. (NCT01032629)
Timeframe: Baseline and end of treatment (approximately 338 weeks)
| Intervention | Ratio (Least Squares Mean) |
|---|---|
| Placebo | -0.04 |
| Canagliflozin 100 mg | -0.02 |
| Canagliflozin 300 mg | 0.00 |
A raised proinsulin-to-insulin ratio due to impaired processing of proinsulin is an early marker of beta cell dysfunction. Beta-cell dysfunction was evaluated by calculating the PI/I ratio, which estimates the capacity of beta cells to convert proinsulin to insulin and may represent an acceptable method to indicate the degree of beta-cell secretion. (NCT01032629)
Timeframe: Baseline and end of treatment (approximately 338 weeks)
| Intervention | Picomole per milli international units (Least Squares Mean) |
|---|---|
| Placebo | 0.70 |
| Canagliflozin 100 mg | 0.67 |
| Canagliflozin 300 mg | 1.03 |
Change from baseline in triglycerides levels was assessed. (NCT01032629)
Timeframe: Baseline and end of treatment (approximately 338 weeks)
| Intervention | mmol/L (Mean) |
|---|---|
| Placebo | 0.05 |
| Canagliflozin 100 mg | 0.13 |
| Canagliflozin 300 mg | 0.09 |
Urinary Albumin/Creatinine Ratio is a potential marker of chronic kidney disease, calculated as a ratio of Urinary Albumin and Urinary Creatinine. (NCT01032629)
Timeframe: Baseline and End of treatment (approximately 338 weeks)
| Intervention | Milligram per gram (mg/g) (Geometric Mean) |
|---|---|
| Placebo | 29.30 |
| Canagliflozin 100 mg | 25.50 |
| Canagliflozin 300 mg | 24.47 |
MACE, defined as a composite of CV death, non-fatal MI, and nonfatal stroke. Adjudication of these events by the Endpoint Adjudication Committee (EAC) was performed in a blinded fashion. Event rate estimated based on the time to the first occurrence of MACE are presented. (NCT01032629)
Timeframe: Up to approximately 8 years
| Intervention | Events per 1000 patient-year (Number) |
|---|---|
| Placebo | 30.36 |
| Canagliflozin 100 mg | 28.41 |
| Canagliflozin 300 mg | 25.37 |
| Canagliflozin (Total) | 26.89 |
Percent change from baseline in body weight was assessed at the end of treatment. (NCT01032629)
Timeframe: Baseline and end of treatment (approximately 338 weeks)
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | -0.50 |
| Canagliflozin 100 mg | -3.47 |
| Canagliflozin 300 mg | -4.12 |
Progression defined as the development of micro-albuminuria (albumin/creatinine ratio (ACR) greater than or equal to [>=] 30 milligram per gram (mg/g) and less than or equal to <= 300 mg/g) or macroalbuminuria (ACR of >300 mg/g) in a participant with baseline normoalbuminuria or the development of macro-albuminuria in a participant with baseline microalbuminuria. Percentage of participants with progression of albuminuria at the end-of-treatment were assessed. (NCT01032629)
Timeframe: End of treatment (approximately 338 weeks)
| Intervention | Percentage of participants (Number) |
|---|---|
| Placebo | 24.0 |
| Canagliflozin 100 mg | 20.2 |
| Canagliflozin 300 mg | 18.3 |
Change from baseline in cholesterol, high-density lipoprotein cholesterol and low density lipoprotein cholesterol levels were assessed. (NCT01032629)
Timeframe: Baseline and end of treatment (approximately 338 weeks)
| Intervention | mmol/L (Least Squares Mean) | ||
|---|---|---|---|
| Cholesterol (change at EOT) | HDL-C (change at EOT) | LDL-C (change at EOT) | |
| Canagliflozin 100 mg | 0.11 | 0.04 | 0.04 |
| Canagliflozin 300 mg | 0.16 | 0.05 | 0.10 |
| Placebo | -0.07 | -0.01 | -0.07 |
Change from baseline in systolic blood pressure and diastolic blood pressure was assessed. (NCT01032629)
Timeframe: Baseline and end of treatment (approximately 338 weeks)
| Intervention | Millimeter of mercury (mmHg) (Least Squares Mean) | |
|---|---|---|
| SBP(Change at end of treatment) | DBP (Change at end of treatment) | |
| Canagliflozin 100 mg | -4.91 | -3.70 |
| Canagliflozin 300 mg | -6.49 | -4.51 |
| Placebo | -1.96 | -2.88 |
Effect size (region of interest z-scores, derived from z-maps of the brain) shown below is the difference in parietal cortex activation to highly desirable (high fat or high calorie, e.g. cakes, pies, fries) versus less desirable (low fat or low calorie, e.g. vegetables, fruits) food cues for each treatment condition (liraglutide or placebo) at the end of the treatment period. (NCT01562678)
Timeframe: 18 days of Liraglutide or placebo treatment
| Intervention | z-scores of activation in cortex (Mean) |
|---|---|
| Liraglutide | -0.42 |
| Placebo | 0.53 |
3 reviews available for 3-hydroxybutyric acid and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
β-hydroxybutyrate: much more than a metabolite.
Topics: 3-Hydroxybutyric Acid; Adipocytes; Diabetes Mellitus, Type 2; Humans; Signal Transduction | 2014 |
Evaluation of the Accuracy of Capillary Hydroxybutyrate Measurement Compared with Other Measurements in the Diagnosis of Diabetic Ketoacidosis: A Systematic Review.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dia | 2016 |
[Blood level of ketone bodies and its clinical significance].
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Biomarkers; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type | 2002 |
22 trials available for 3-hydroxybutyric acid and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Reduction of De Novo Lipogenesis Mediates Beneficial Effects of Isoenergetic Diets on Fatty Liver: Mechanistic Insights from the MEDEA Randomized Clinical Trial.
Topics: 3-Hydroxybutyric Acid; Diabetes Mellitus, Type 2; Diet; Humans; Lipogenesis; Non-alcoholic Fatty Liv | 2022 |
Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS).
Topics: 3-Hydroxybutyric Acid; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Fasting; G | 2022 |
Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Citrates; Cohort Studies; Diabetes Mellitus, Type 2; Gastrecto | 2023 |
Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Citrates; Cohort Studies; Diabetes Mellitus, Type 2; Gastrecto | 2023 |
Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Citrates; Cohort Studies; Diabetes Mellitus, Type 2; Gastrecto | 2023 |
Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Citrates; Cohort Studies; Diabetes Mellitus, Type 2; Gastrecto | 2023 |
Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Citrates; Cohort Studies; Diabetes Mellitus, Type 2; Gastrecto | 2023 |
Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Citrates; Cohort Studies; Diabetes Mellitus, Type 2; Gastrecto | 2023 |
Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Citrates; Cohort Studies; Diabetes Mellitus, Type 2; Gastrecto | 2023 |
Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Citrates; Cohort Studies; Diabetes Mellitus, Type 2; Gastrecto | 2023 |
Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Citrates; Cohort Studies; Diabetes Mellitus, Type 2; Gastrecto | 2023 |
Effects of β-hydroxybutyrate on cognition in patients with type 2 diabetes.
Topics: 3-Hydroxybutyric Acid; Aged; Blood Glucose; Cognition; Cross-Over Studies; Diabetes Mellitus, Type 2 | 2020 |
Circulating lipids in men with type 2 diabetes following 3 days on a carbohydrate-free diet versus 3 days of fasting.
Topics: 3-Hydroxybutyric Acid; Aged; Biomarkers; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type | 2020 |
Type 2 Diabetes Prevention Focused on Normalization of Glycemia: A Two-Year Pilot Study.
Topics: 3-Hydroxybutyric Acid; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diet, Carbohydrate-Res | 2021 |
Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co-transporter 2 inhibitor canagliflozin.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Biological Variation, Population; Blood Glucose; Canagliflozin | 2018 |
Purified anthocyanin supplementation reduces dyslipidemia, enhances antioxidant capacity, and prevents insulin resistance in diabetic patients.
Topics: 3-Hydroxybutyric Acid; Aged; Anthocyanins; Antioxidants; Apolipoprotein B-48; Apolipoprotein C-III; | 2015 |
Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
Topics: 3-Hydroxybutyric Acid; Algorithms; Benzhydryl Compounds; C-Reactive Protein; Carbohydrate Metabolism | 2016 |
Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
Topics: 3-Hydroxybutyric Acid; Algorithms; Benzhydryl Compounds; C-Reactive Protein; Carbohydrate Metabolism | 2016 |
Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
Topics: 3-Hydroxybutyric Acid; Algorithms; Benzhydryl Compounds; C-Reactive Protein; Carbohydrate Metabolism | 2016 |
Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
Topics: 3-Hydroxybutyric Acid; Algorithms; Benzhydryl Compounds; C-Reactive Protein; Carbohydrate Metabolism | 2016 |
Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
Topics: 3-Hydroxybutyric Acid; Algorithms; Benzhydryl Compounds; C-Reactive Protein; Carbohydrate Metabolism | 2016 |
Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
Topics: 3-Hydroxybutyric Acid; Algorithms; Benzhydryl Compounds; C-Reactive Protein; Carbohydrate Metabolism | 2016 |
Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
Topics: 3-Hydroxybutyric Acid; Algorithms; Benzhydryl Compounds; C-Reactive Protein; Carbohydrate Metabolism | 2016 |
Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
Topics: 3-Hydroxybutyric Acid; Algorithms; Benzhydryl Compounds; C-Reactive Protein; Carbohydrate Metabolism | 2016 |
Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
Topics: 3-Hydroxybutyric Acid; Algorithms; Benzhydryl Compounds; C-Reactive Protein; Carbohydrate Metabolism | 2016 |
Postprandial carbohydrate metabolism in healthy subjects and those with type 2 diabetes fed starches with slow and rapid hydrolysis rates determined in vitro.
Topics: 3-Hydroxybutyric Acid; Adult; Blood Glucose; Carbon Dioxide; Cross-Over Studies; Diabetes Mellitus, | 2003 |
Effect of a high-protein, low-carbohydrate diet on blood glucose control in people with type 2 diabetes.
Topics: 3-Hydroxybutyric Acid; Aged; Aged, 80 and over; Blood Glucose; Body Weight; Cross-Over Studies; Diab | 2004 |
Effect of a high-protein, low-carbohydrate diet on blood glucose control in people with type 2 diabetes.
Topics: 3-Hydroxybutyric Acid; Aged; Aged, 80 and over; Blood Glucose; Body Weight; Cross-Over Studies; Diab | 2004 |
Effect of a high-protein, low-carbohydrate diet on blood glucose control in people with type 2 diabetes.
Topics: 3-Hydroxybutyric Acid; Aged; Aged, 80 and over; Blood Glucose; Body Weight; Cross-Over Studies; Diab | 2004 |
Effect of a high-protein, low-carbohydrate diet on blood glucose control in people with type 2 diabetes.
Topics: 3-Hydroxybutyric Acid; Aged; Aged, 80 and over; Blood Glucose; Body Weight; Cross-Over Studies; Diab | 2004 |
The effects of diet, sulfonylurea, and Repaglinide therapy on clinical and metabolic parameters in type 2 diabetic patients during Ramadan.
Topics: 3-Hydroxybutyric Acid; Blood Glucose; Carbamates; Cholesterol, HDL; Diabetes Mellitus, Type 2; Fasti | 2004 |
Metabolic and endothelial effects of trimetazidine on forearm skeletal muscle in patients with type 2 diabetes and ischemic cardiomyopathy.
Topics: 3-Hydroxybutyric Acid; Aged; Blood Glucose; Citric Acid; Cross-Over Studies; Cyclic GMP; Diabetes Me | 2006 |
The role of plasma non-esterified fatty acids during exercise in type 2 diabetes mellitus.
Topics: 3-Hydroxybutyric Acid; Blood Glucose; C-Peptide; Calorimetry; Carbon Dioxide; Diabetes Mellitus, Typ | 1993 |
The effects of changes in plasma nonesterified fatty acid levels on oxidative metabolism during moderate exercise in patients with non-insulin-dependent diabetes mellitus.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Blood Glucose; Calorimetry, Indirect; Diabetes Mellitus, Type | 1993 |
Effects of an acute decrease in non-esterified fatty acid levels on muscle glucose utilization and forearm indirect calorimetry in lean NIDDM patients.
Topics: 3-Hydroxybutyric Acid; Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Forearm | 1996 |
Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo.
Topics: 3-Hydroxybutyric Acid; Appetite Depressants; Body Weight; C-Peptide; Diabetes Mellitus; Diabetes Mel | 1996 |
High plasma free fatty acids decrease splanchnic glucose uptake in patients with non-insulin-dependent diabetes mellitus.
Topics: 3-Hydroxybutyric Acid; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Fasting; Fat Emulsions, | 1998 |
Effects of high-dose glucose-insulin-potassium on myocardial metabolism after coronary surgery in patients with Type II diabetes.
Topics: 3-Hydroxybutyric Acid; Aged; Analysis of Variance; Angina Pectoris; Cardiopulmonary Bypass; Catheter | 2001 |
Acute metabolic and hormonal responses to the inhibition of lipolysis in non-obese patients with non-insulin-dependent (type 2) diabetes mellitus: effects of acipimox.
Topics: 3-Hydroxybutyric Acid; Blood Glucose; Diabetes Mellitus, Type 2; Epinephrine; Fatty Acids, Nonesteri | 1992 |
Metabolic effects of suppression of nonesterified fatty acid levels with acipimox in obese NIDDM subjects.
Topics: 3-Hydroxybutyric Acid; Alanine; Blood Glucose; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Ty | 1992 |
Effects of BAYm 1099, new alpha-glucosidase inhibitor, on acute metabolic responses and metabolic control in NIDDM over 1 mo.
Topics: 1-Deoxynojirimycin; 3-Hydroxybutyric Acid; Alanine; Blood Glucose; Clinical Trials as Topic; Diabete | 1988 |
71 other studies available for 3-hydroxybutyric acid and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Ketone Ester D-β-Hydroxybutyrate-(R)-1,3 Butanediol Prevents Decline in Cardiac Function in Type 2 Diabetic Mice.
Topics: 3-Hydroxybutyric Acid; Animals; Butylene Glycols; Diabetes Mellitus, Experimental; Diabetes Mellitus | 2021 |
Exogenous d-β-hydroxybutyrate lowers blood glucose in part by decreasing the availability of L-alanine for gluconeogenesis.
Topics: 3-Hydroxybutyric Acid; Alanine; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Glucon | 2022 |
Beta-Hydroxybutyric Acid Inhibits Renal Tubular Reabsorption via the AKT/DAB2/Megalin Signalling Pathway.
Topics: 3-Hydroxybutyric Acid; Adaptor Proteins, Signal Transducing; Albumins; Apoptosis Regulatory Proteins | 2022 |
Euglycemic Diabetic Ketoacidosis Caused by Alcoholic Pancreatitis and Starvation Ketosis.
Topics: 3-Hydroxybutyric Acid; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Humans; Male; Middl | 2023 |
β-hydroxybutyrate as a biomarker of β-cell function in new-onset type 2 diabetes and its association with treatment response at 6 months.
Topics: 3-Hydroxybutyric Acid; Biomarkers; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Ketone Bo | 2023 |
Impaired ketogenesis is associated with metabolic-associated fatty liver disease in subjects with type 2 diabetes.
Topics: 3-Hydroxybutyric Acid; Adipose Tissue; CD36 Antigens; Diabetes Mellitus, Type 2; Humans; Non-alcohol | 2023 |
Impact on Diabetic Ketoacidosis Resolution After Implementation of a 2-Bag Fluid Order Set.
Topics: 3-Hydroxybutyric Acid; Adult; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Humans; Hypoglycemic | 2023 |
Fasting Ketone Bodies and Incident Type 2 Diabetes in the General Population.
Topics: 3-Hydroxybutyric Acid; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Humans; Ketone | 2023 |
Complementary effects of dapagliflozin and lobeglitazone on metabolism in a diet-induced obese mouse model.
Topics: 3-Hydroxybutyric Acid; Animals; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diet | 2023 |
A J-shaped relationship between ketones and the risk of diabetic kidney disease in patients with type 2 diabetes: New insights from a cross-sectional study.
Topics: 3-Hydroxybutyric Acid; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; H | 2023 |
The Significance of an Increased Beta-Hydroxybutyrate at Presentation to the Emergency Department in Patients with Diabetes in the Absence of a Hyperglycemic Emergency.
Topics: 3-Hydroxybutyric Acid; Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Child; Child, Pres | 2019 |
Pre-diagnostic biomarkers of type 2 diabetes identified in the UAE's obese national population using targeted metabolomics.
Topics: 3-Hydroxybutyric Acid; Adult; Alanine; Amino Acids, Branched-Chain; Biomarkers; Chromatography, Liqu | 2020 |
Association of higher arterial ketone body ratio (acetoacetate/β-hydroxybutyrate) with relevant nutritional marker in hemodialysis patients.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Aged; Biomarkers; Diabetes Mellitus, Type 2; Female; Humans; K | 2020 |
Long-term obestatin treatment of mice type 2 diabetes increases insulin sensitivity and improves liver function.
Topics: 3-Hydroxybutyric Acid; Adenylate Kinase; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diet, Hi | 2017 |
Maternal BMI and Glycemia Impact the Fetal Metabolome.
Topics: 3-Hydroxybutyric Acid; Adiposity; Adult; Amino Acids, Branched-Chain; Birth Weight; Blood Glucose; B | 2017 |
Degree of ketonaemia and its association with insulin resistance after dapagliflozin treatment in type 2 diabetes.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Adult; Aged; Benzhydryl Compounds; Case-Control Studies; Diabe | 2018 |
Trypanosoma evansi induces detrimental immuno-catabolic alterations and condition like type-2 diabetes in buffaloes.
Topics: 3-Hydroxybutyric Acid; Animals; Antioxidants; Blood Chemical Analysis; Buffaloes; Diabetes Mellitus, | 2018 |
Eruptive xanthomas in a patient with soft-drink diabetic ketosis and apolipoprotein E4/2.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Adolescent; Apolipoprotein E2; Apolipoprotein E4; Carbonated B | 2019 |
Ketoacidosis in Euglycemic Patients With Type 2 Diabetes After Abdominal Surgery.
Topics: 3-Hydroxybutyric Acid; Abdomen; Acidosis; Aged; Anions; Bicarbonates; Blood Glucose; Diabetes Mellit | 2019 |
Elevated β-hydroxybutyric acid with no ketoacidosis in type 2 diabetic patients using sodium-glucose cotransporter-2 inhibitors.
Topics: 3-Hydroxybutyric Acid; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Humans; Ketosis; Sodium-Glu | 2019 |
Hypermetabolism and impaired endothelium-dependent vasodilation in mesenteric arteries of type 2 diabetes mellitus db/db mice.
Topics: 3-Hydroxybutyric Acid; Animals; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Models, An | 2019 |
Association of ketone body levels with hyperglycemia and type 2 diabetes in 9,398 Finnish men.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Area Under Curve; Biomarkers; Blood Glucose; Diabetes Mellitus | 2013 |
Biochemical efficacy of vitamin D in ameliorating endocrine and metabolic disorders in diabetic rats.
Topics: 3-Hydroxybutyric Acid; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, T | 2014 |
Breath acetone to monitor life style interventions in field conditions: an exploratory study.
Topics: 3-Hydroxybutyric Acid; Acetone; Adult; Aged; Breath Tests; Case-Control Studies; Diabetes Mellitus, | 2014 |
[Establishment of blood β-hydroxybutyrate threshold for diagnosis of type 2 diabetes ketoacidosis].
Topics: 3-Hydroxybutyric Acid; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Humans; Sensitivity and Spe | 2014 |
Analysis of ketone bodies in exhaled breath and blood of ten healthy Japanese at OGTT using a portable gas chromatograph.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Acetone; Adult; Asian People; Blood Glucose; Breath Tests; Chr | 2014 |
Taming the inflammasome.
Topics: 3-Hydroxybutyric Acid; Atherosclerosis; Carrier Proteins; Diabetes Mellitus, Type 2; Gout; Humans; I | 2015 |
The extracellular redox state modulates mitochondrial function, gluconeogenesis, and glycogen synthesis in murine hepatocytes.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Animals; Cysteine; Cystine; Diabetes Mellitus, Type 2; Glucone | 2015 |
Metabolite profiling in plasma and tissues of ob/ob and db/db mice identifies novel markers of obesity and type 2 diabetes.
Topics: 3-Hydroxybutyric Acid; Adipose Tissue; Animals; Diabetes Mellitus, Type 2; Fatty Acids; Gas Chromato | 2015 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; | 2016 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; | 2016 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; | 2016 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; | 2016 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; | 2016 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; | 2016 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; | 2016 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; | 2016 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; | 2016 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; | 2016 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; | 2016 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; | 2016 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; | 2016 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; | 2016 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; | 2016 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; | 2016 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; | 2016 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; | 2016 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; | 2016 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; | 2016 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; | 2016 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; | 2016 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; | 2016 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; | 2016 |
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; | 2016 |
The role of point-of-care 3-hydroxybutyrate testing in patients with type 2 diabetes undergoing coronary angiography.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Aged; Blood Glucose; Coronary Angiography; Coronary Disease; D | 2017 |
Ablation of ARNT/HIF1beta in liver alters gluconeogenesis, lipogenic gene expression, and serum ketones.
Topics: 3-Hydroxybutyric Acid; Adult; AMP-Activated Protein Kinases; Animals; Aryl Hydrocarbon Receptor Nucl | 2009 |
Protective effects of mildronate in an experimental model of type 2 diabetes in Goto-Kakizaki rats.
Topics: 3-Hydroxybutyric Acid; Administration, Oral; Animals; Blood Glucose; Cardiovascular Agents; Carnitin | 2009 |
The performance of a glucose-ketone meter in the diagnosis of diabetic ketoacidosis in patients with type 2 diabetes in the emergency room.
Topics: 3-Hydroxybutyric Acid; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Emergency Me | 2010 |
Proteomics analysis reveals diabetic kidney as a ketogenic organ in type 2 diabetes.
Topics: 3-Hydroxybutyric Acid; Animals; Blotting, Western; Cells, Cultured; Collagen Type I; Diabetes Mellit | 2011 |
Effect of trans-fat, fructose and monosodium glutamate feeding on feline weight gain, adiposity, insulin sensitivity, adipokine and lipid profile.
Topics: 3-Hydroxybutyric Acid; Absorptiometry, Photon; Adipokines; Adipose Tissue; Adiposity; Animals; Bioma | 2011 |
Hepatic expression of cytochrome P450 in type 2 diabetic Goto-Kakizaki rats.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Animals; Blood Glucose; Cytochrome P-450 CYP1A1; Cytochrome P- | 2012 |
Metabolomic profilings of urine and serum from high fat-fed rats via 1H NMR spectroscopy and pattern recognition.
Topics: 3-Hydroxybutyric Acid; Animals; Choline; Citric Acid; Creatinine; Diabetes Mellitus, Type 2; Dietary | 2013 |
A metabolomic study on the effect of intravascular laser blood irradiation on type 2 diabetic patients.
Topics: 3-Hydroxybutyric Acid; Amino Acids; Blood Glucose; Dehydroascorbic Acid; Diabetes Mellitus, Type 2; | 2013 |
Reduced SOD activity and increased neural tube defects in embryos of the sensitive but not of the resistant Cohen diabetic rats cultured under diabetic conditions.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Animals; Catalase; Diabetes Mellitus, Type 2; Disease Models, | 2003 |
Effects of high carbohydrate and high fat diet on plasma metabolite levels and on i.v. glucose tolerance test in intact and neutered male cats.
Topics: 3-Hydroxybutyric Acid; Animals; Blood Glucose; Case-Control Studies; Cat Diseases; Cats; Cholesterol | 2004 |
Real-time assessment of postprandial fat storage in liver and skeletal muscle in health and type 2 diabetes.
Topics: 3-Hydroxybutyric Acid; Area Under Curve; Blood Glucose; Chylomicrons; Diabetes Mellitus, Type 2; Die | 2005 |
A retinoid X receptor antagonist, HX531, improves leptin resistance without increasing plasma leptin level in KK-Ay mice under normal dietary conditions.
Topics: 3-Hydroxybutyric Acid; Adipose Tissue; Animals; Benzoates; Biphenyl Compounds; Body Temperature; Bod | 2005 |
Ketone bodies alter dinitrophenol-induced glucose uptake through AMPK inhibition and oxidative stress generation in adult cardiomyocytes.
Topics: 2,4-Dinitrophenol; 3-Hydroxybutyric Acid; Acetyl-CoA Carboxylase; Acetylcysteine; AMP-Activated Prot | 2007 |
Analysis of factors influencing nitrogen balance during acute starvation in obese subject with and without type 2 diabetes.
Topics: 3-Hydroxybutyric Acid; Adipose Tissue; Area Under Curve; Blood Glucose; Body Composition; Calorimetr | 2007 |
Can serum beta-hydroxybutyrate be used to diagnose diabetic ketoacidosis?
Topics: 3-Hydroxybutyric Acid; Adolescent; Adult; Bicarbonates; Biomarkers; Blood Glucose; Child; Diabetes M | 2008 |
Angiotensin-converting enzyme in diabetes mellitus dependence on metabolic aberration.
Topics: 3-Hydroxybutyric Acid; Adolescent; Adult; Aged; Blood Glucose; Carbon Dioxide; Diabetes Mellitus, Ty | 1983 |
Proton-nuclear-magnetic-resonance studies of serum, plasma and urine from fasting normal and diabetic subjects.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Acetone; Adult; Amino Acids; Diabetes Mellitus, Type 1; Diabet | 1984 |
The effect of the fat content of food on the pharmacokinetics and pharmacodynamics of SDZ FOX 988, an antidiabetic agent, in the dog.
Topics: 3-Hydroxybutyric Acid; Absorption; Acetophenones; Administration, Oral; Animals; Benzoates; Blood Gl | 1995 |
Glucose metabolism during the starved-to-fed transition in obese patients with NIDDM.
Topics: 3-Hydroxybutyric Acid; Adult; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fasting; | 1994 |
Circulating lipids and cardiovascular risk in newly diagnosed non-insulin-dependent diabetic subjects in India.
Topics: 3-Hydroxybutyric Acid; Adult; Albuminuria; Angina Pectoris; Cardiovascular Diseases; Cholesterol; Co | 1997 |
Alcoholic ketoacidosis at autopsy.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Acetone; Adolescent; Adult; Aged; Aged, 80 and over; Alcoholis | 1998 |
Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus.
Topics: 3-Hydroxybutyric Acid; Adult; Alanine; Arteries; Diabetes Mellitus, Type 2; Energy Metabolism; Fatty | 1998 |
Effect of pravastatin on plasma ketone bodies in diabetics with hypercholesterolemia.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Aged; Aged, 80 and over; Body Mass Index; Cholesterol; Diabete | 1998 |
Acute lowering of plasma fatty acids lowers basal insulin secretion in diabetic and nondiabetic subjects.
Topics: 3-Hydroxybutyric Acid; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Emulsions; Fat Emulsions, Int | 1998 |
Effects of fatty acids and ketone bodies on basal insulin secretion in type 2 diabetes.
Topics: 3-Hydroxybutyric Acid; Aged; C-Peptide; Diabetes Mellitus, Type 2; Fat Emulsions, Intravenous; Fatty | 1999 |
Skin mini-erosion technique for monitoring metabolites in interstitial fluid: its feasibility demonstrated by OGTT results in diabetic and non-diabetic subjects.
Topics: 3-Hydroxybutyric Acid; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Extracellular Space; Female; | 1999 |
Assessment of the nutritional value of glycerol-1,2, 3-tris(methylsuccinate) in fed and starved rats.
Topics: 3-Hydroxybutyric Acid; Animals; Blood Glucose; Body Weight; Chloride Channels; Diabetes Mellitus, Ty | 1999 |
Myocardial uptake and release of substrates in type II diabetics undergoing coronary surgery.
Topics: 3-Hydroxybutyric Acid; Coronary Artery Bypass; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified | 2001 |
What if Minkowski had been ageusic? An alternative angle on diabetes.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Adipose Tissue; Blood Glucose; Diabetes Mellitus, Type 1; Diab | 1992 |
Dietary substitution of medium-chain triglycerides improves insulin-mediated glucose metabolism in NIDDM subjects.
Topics: 3-Hydroxybutyric Acid; Adipose Tissue; Adult; Blood Glucose; Carnitine; Diabetes Mellitus, Type 2; F | 1992 |
Serum ketone response to glucagon as a marker of insulin dependency in diabetics.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Adult; Biomarkers; Blood Glucose; C-Peptide; Diabetes Mellitus | 1991 |
Blood ketone bodies in NIDDM: relationship with diabetic control and endogenous insulin secretion.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Die | 1991 |
Impaired activation of skeletal muscle glycogen synthase in non-insulin-dependent diabetes mellitus is unrelated to the degree of obesity.
Topics: 3-Hydroxybutyric Acid; C-Peptide; Diabetes Mellitus, Type 2; Fasting; Fatty Acids, Nonesterified; Fe | 1991 |
Inhibition by etomoxir of carnitine palmitoyltransferase I reduces hepatic glucose production and plasma lipids in non-insulin-dependent diabetes mellitus.
Topics: 3-Hydroxybutyric Acid; Adult; Alanine Transaminase; Carnitine O-Palmitoyltransferase; Cholesterol; D | 1991 |
Effects of chronic alcohol intake on carbohydrate and lipid metabolism in subjects with type II (non-insulin-dependent) diabetes.
Topics: 3-Hydroxybutyric Acid; Aged; Alcohol Drinking; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Typ | 1991 |
Diurnal variation of blood ketone bodies in insulin-dependent diabetes mellitus and noninsulin-dependent diabetes mellitus patients: the relationship to serum C-peptide immunoreactivity and free insulin.
Topics: 3-Hydroxybutyric Acid; Adolescent; Adult; Aged; Blood Glucose; C-Peptide; Circadian Rhythm; Diabetes | 1990 |
To what extent can metabolism be 'normalized' in insulin-dependent diabetes?
Topics: 3-Hydroxybutyric Acid; Alanine; Blood Glucose; Diabetes Mellitus, Type 2; Evaluation Studies as Topi | 1990 |
Carbohydrate tolerance improves with fasting in obese subjects with noninsulin-dependent (type II) diabetes.
Topics: 3-Hydroxybutyric Acid; Adult; Blood Glucose; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2 | 1990 |
Direct evidence for a stimulatory effect of hyperglycemia per se on peripheral glucose disposal in type II diabetes.
Topics: 3-Hydroxybutyric Acid; Adult; Alanine; C-Peptide; Diabetes Mellitus, Type 2; Female; Hemoglobin A; H | 1986 |
Insulin infusion (GIK) in the treatment of type 2 (non-insulin dependent) diabetes during the perioperative period.
Topics: 3-Hydroxybutyric Acid; Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glucose | 1986 |